Evidence map›Paper›PMID 21091909›Full record

ArticleImmunology2011

Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells.

Sandhya Subramanian, Melissa Yates, Arthur A Vandenbark, Halina Offner

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Sex as a biological variable: Mechanistic insights and clinical relevance in solid organ transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023
    Review
  3. Article
  4. Review
  5. Sex, Cells, and Asthma.Mayo Clinic proceedings · 2021
    Review
  6. Article
  7. Article
  8. Sex bias in autoimmunity.Current opinion in rheumatology · 2019
    Review
  9. Review
  10. Glucocorticoids, Sex Hormones, and Immunity.Frontiers in immunology · 2018
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sandhya SubramanianNeuroimmunology Research, Veterans' Affairs Medical Center, Portland, OR 97239, USA.
Melissa Yates
Arthur A Vandenbark
Halina Offner
Oregon Health & Science University · USPortland VA Medical Center · US

Funding

Tissue AnalysisP01NS049210 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI RØNNEKLEIV, OLINE KARIN · 2005 to 2009
$6.9M
IMMUNOREGULATORY EFFECTS OF ESTROGEN IN EAER01NS045445 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI OFFNER, HALINA · 2002 to 2010
$2.7M
NINDS NIH HHS P01 NS049210NINDS NIH HHS R01 NS045445
6 · The paper itself

Abstract

Oestrogen (17β-oestradiol, E₂) is a highly effective treatment for experimental autoimmune encephalomyelitis (EAE) that may potentiate Foxp3+ regulatory T (Treg) cells, which in turn limit the expansion of encephalitogenic T-cell specificities. To determine if Treg cells constitute the major non-redundant protective pathway for E₂, we evaluated E₂ protection of EAE after targeted deletion of Foxp3 expression in Foxp3-DTR mice. Unexpectedly, E₂-treated Foxp3-deficient mice were completely protected against clinical and histological myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide-induced EAE before succumbing to diphtheria toxin-induced mortality. This finding indicated the presence of alternative E₂-dependent EAE-protective pathways that could compensate for the lack of Treg cells. Further investigation revealed that E₂ treatment inhibited proliferation and expression of CCL2 and CXCL2, but enhanced secretion of interleukin-10 (IL-10) and IL-13 by MOG-35-55-specific spleen cells. These changes occurred concomitantly with increased expression of several chemokines and receptors, including CXCL13 and CXCR5, and the negative co-activation molecules, PD-L1 and B7.2, by B cells and dendritic cells. Furthermore, E₂ treatment resulted in higher percentages of spleen and lymph node T cells expressing IL-17, interferon-γ and tumour necrosis factor-α, but with lower expression of CCR6, suggesting sequestration of MOG-35-55 peptide-specific T cells in peripheral immune organs. Taken together, these data suggest that E₂-induced mechanisms that provide protection against EAE in the absence of Foxp3+ Treg cells include induction of regulatory B cells and peripheral sequestration of encephalitogenic T cells.

Indexed as

AnimalsB-LymphocytesB-Lymphocyte SubsetsCell ProliferationCell SeparationCytokinesEncephalomyelitis, Autoimmune, ExperimentalEstradiolEstrogensFemaleFlow CytometryForkhead Transcription FactorsMiceReverse Transcriptase Polymerase Chain ReactionT-Lymphocytes, RegulatoryCytokinesEstradiolEstrogensForkhead Transcription FactorsFoxp3 protein, mouse

Identifiers

PMID21091909
PMCPMC3044900
OpenAlexW1563022589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.